Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healios KK ( (JP:4593) ) has provided an announcement.
Healios KK has launched a new Medical Materials and Equipment Division to ensure a stable supply of culture supernatants and expand its related business. This division will lead efforts in manufacturing optimization, market research, and sales strategy formulation, particularly as the company prepares for the potential approval of its ARDS treatment in Japan. The collaboration with AND medical group signifies an important step in utilizing culture supernatant for new treatments and cosmetics, positioning Healios strategically in the regenerative medicine market.
More about Healios KK
Healios KK operates in the regenerative medicine industry and primarily focuses on developing and distributing cell therapy products. Their flagship product, MultiStem, is a somatic stem cell regenerative medicine used for treating ischemic stroke and acute respiratory distress syndrome (ARDS), with plans for global expansion.
YTD Price Performance: 12.99%
Average Trading Volume: 816,544
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen18.12B
See more insights into 4593 stock on TipRanks’ Stock Analysis page.